As announced on Monday evening, the Phase III stage Livatag did not meet the primary endpoint of improving survival in hepatocellular carcinoma (HCC) patients after treatment failure with sorafenib over the comparison arm, where patients received the standard of care (SoC). This morning, Onxeo announced that it had out-licensed its Phase III ready orphan oncology asset Validive to Monopar Therapeutics for a total deal value of $108m and up to double-digit royalties.
14 Sep 2017
Onxeo - Livatag's future less clear; Validive finds partner
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Onxeo - Livatag's future less clear; Validive finds partner
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
14 Sep 2017 -
Author:
Dr Jonas Peciulis -
Pages:
2
As announced on Monday evening, the Phase III stage Livatag did not meet the primary endpoint of improving survival in hepatocellular carcinoma (HCC) patients after treatment failure with sorafenib over the comparison arm, where patients received the standard of care (SoC). This morning, Onxeo announced that it had out-licensed its Phase III ready orphan oncology asset Validive to Monopar Therapeutics for a total deal value of $108m and up to double-digit royalties.